2014
DOI: 10.1186/1479-5876-12-41
|View full text |Cite
|
Sign up to set email alerts
|

Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor

Abstract: BackgroundGastrointestinal stromal tumor (GIST) is the most common sarcoma and its treatment with imatinib has served as the paradigm for developing targeted anti-cancer therapies. Despite this success, imatinib-resistance has emerged as a major problem and therefore, the clinical efficacy of other drugs has been investigated. Unfortunately, most clinical trials have failed to identify efficacious drugs despite promising in vitro data and pathological responses in subcutaneous xenografts. We hypothesized that … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(17 citation statements)
references
References 39 publications
0
17
0
Order By: Relevance
“…However, the method requires specific technical skill and experience in animal models. But despite the significantly higher technical complexity and higher costs, such patient-derived orthotopic xenografts models can better recapitulate the biology of the human disease and thus facilitating the investigation of novel treatment strategies in a setting that more closely resembles the human primary tumor [ 29 - 33 ]. We are currently employing this novel tool to identify new compounds for the systemic treatment of osteosarcoma and for developing new strategies to achieve local control by heavy ion radiotherapy [ 34 , 35 ].…”
Section: Discussionmentioning
confidence: 99%
“…However, the method requires specific technical skill and experience in animal models. But despite the significantly higher technical complexity and higher costs, such patient-derived orthotopic xenografts models can better recapitulate the biology of the human disease and thus facilitating the investigation of novel treatment strategies in a setting that more closely resembles the human primary tumor [ 29 - 33 ]. We are currently employing this novel tool to identify new compounds for the systemic treatment of osteosarcoma and for developing new strategies to achieve local control by heavy ion radiotherapy [ 34 , 35 ].…”
Section: Discussionmentioning
confidence: 99%
“…In this regard, advanced real-time imaging systems permit the quantitative assessment of primary tumour growth and metastatic progression, relying on the use of imaging modalities. In relation to this, Fluorodeoxyglucose–positron emission tomography (FDG-PET) has been proposed and the feasibility of this technique has been confirmed by magnetic resonance [34, 35]. Furthermore, based on the observation that more than 90% of pancreatic cancers are EGFR-positive, a novel imaging approach which combines micro PET and F(ab’)2 fragments of the fully-human anti-EGFR monoclonal antibody, panitumumab has been evaluated [36].…”
Section: Limits and Challenges Of Pdx Modelsmentioning
confidence: 99%
“…A number of recent studies have reported using orthotopic transplant to generate models of GC using cell lines or patient derived tumours. Implantation methods include subserosal injection of cells 7 , subserosal implantation of tumour pieces 8 as well as attachment of tumour pieces using OB glue 9 or by stitching 10 . All of these models result in tumour formation at the implantation site and in some cases are associated with local invasion into the liver or distant metastasis to other sites.…”
Section: Introductionmentioning
confidence: 99%